Insulin degludec improves long‐term glycaemic control similarly to insulin glargine but with fewer hypoglycaemic episodes in patients with advanced type 2 diabetes on basal‐bolus insulin therapy

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 2, 2015-02 ,pp. : 202-206

John Wiley & Sons Inc

Access to resources Recommend Favorite

Adherence patterns in patients with type 2 diabetes on basal insulin analogues: missed, mistimed and reduced doses

By Brod Meryl   Rana Azhar   Barnett Anthony H.  

Current Medical Research and Opinion, Vol. 28, Iss. 12, 2012-12 ,pp. : 1933-1946

Informa Healthcare

Access to resources Recommend Favorite

Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo‐controlled trial

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 11, 2015-11 ,pp. : 1056-1064

John Wiley & Sons Inc

Access to resources Recommend Favorite

Effect of pramlintide as an adjunct to basal insulin on markers of cardiovascular risk in patients with type 2 diabetes

By Wysham Carol   Lush Cameron   Zhang Bei   Maier Holly   Wilhelm Ken  

Current Medical Research and Opinion, Vol. 24, Iss. 1, 2008-01 ,pp. : 79-85

Informa Healthcare

Access to resources Recommend Favorite

Comparison of basal insulin therapies with regard to the risk of acute myocardial infarction in patients with type 2 diabetes: an observational cohort study

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 12, 2015-12 ,pp. : 1158-1165

John Wiley & Sons Inc

Access to resources Recommend Favorite